Author

D.A. Smith

Observed name: D. Smith

Observed institutions: University of North Carolina at Chapel Hill, Duke University, Hospital of the University of Pennsylvania, Sarah Cannon, UNC Lineberger Comprehensive Cancer Center, Case Western Reserve University, University of Pennsylvania

OpenAlex ID: A5048847209

14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)

2015 · J. Vansteenkiste, L. Fehrenbacher, et al. · European Journal of Cancer · 36

Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study

2004 · E. C. Dees, H. Burris, et al. · Journal of Clinical Oncology · 15

431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors

2008 · S. Blagden, D. Olmos, et al. · European Journal of Cancer Supplements · 4

9148 Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib (E) and bevacizumab (B) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC)

2009 · D.A. Smith, P. Conkling, et al. · European Journal of Cancer Supplements · 2

72: Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer

2017 · S. Hunter, G. Nickless, et al. · Lung Cancer

Dose-limiting Pneumonitis in a Phase I Trial of R115777 and Radiation Therapy (RT) for Patients (Pts) with Non-small Cell Lung Cancer (NSCLC)

2008 · A.D. Thukral, R. Mick, et al. · International Journal of Radiation Oncology*Biology*Physics

Works count: 6

Citation count: 57

H-index: 3

I10-index: 2